Rhodes, Jonathan M. http://orcid.org/0000-0002-1302-260X
Subramanian, Sreedhar
Flanagan, Paul K.
Horgan, Graham W.
Martin, Kate
Mansfield, John
Parkes, Miles
Hart, Ailsa
Dallal, Helen
Iqbal, Tariq
Butterworth, Jeffrey
Culshaw, Kate
Probert, Christopher
Funding for this research was provided by:
Crohn's and Colitis UK (M/12/3)
Article History
Received: 27 May 2020
Accepted: 4 July 2020
First Online: 17 July 2020
Compliance with Ethical Standards
:
: JMR has been a member of advisory boards for Atlantic, Pharmacosmos, Procter and Gamble, and Vifor and Falk, has received speaking honoraria from Abbott, Allergan, Falk, Ferring, Glaxo Smith Kline, Merck, Procter and Gamble, Schering Plough, Shire, and Wyeth, and with the University of Liverpool and Provexis UK, holds a patent for use of a soluble fiber preparation as maintenance therapy for Crohn’s disease plus a patent for its use in antibiotic-associated diarrhea. The patent also held with the University of Liverpool and others in relation to use of modified heparins in cancer therapy. SS has received speaker fee from MSD, Actavis, Abbvie, Dr Falk pharmaceuticals, Shire, and received educational grant from MSD, Abbvie, and Actavis, and is an advisory board member for Abbvie, Dr Falk Pharma, and Vifor. PKF received a Shire Innovation Fund award and has received funded conference travel from Shire and Tillotts. GWH has provided consultancy for Provexis, Nutricia, and 4DPharma. AH has served as a consultant, advisory board member, or speaker for AbbVie, Arena, Atlantic, Bristol-Myers Squibb, Celgene, Celltrion, Falk, Ferring, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Shire, and Takeda. She also serves on the Global Steering Committee for Genentech. CP has received speaker fees from Vifor, payment for advisory board attendance from Dr Falk Pharma, and support for attendance to other meetings from Dr Falk Pharma and Vifor. The other authors have no competing interests.